AKERO THEREP.INC.DL-,0001

The merger with Novo Nordisk is complete; Akero becomes a wholly owned subsidiary of Novo Nordisk. Each outstanding common share was (with exceptions) converted into the right to receive $54.00 in cash; shareholders also receive a CVR for up to $6.00 if an approval milestone for efruxifermin is achieved. Trading in Akero shares has been suspended, a Form 25 has been filed for formal delisting from the NASDAQ, and the board and management resigned in favor of directors from NN Invest Sub. » More on de.investing.com

Shareholders of Akero Therapeutics voted in favor of the takeover by Novo Nordisk: of 67,029,108 shares present, 66,887,600 voted for the merger. The transaction provides $54.00 in cash per share plus a contingent value right of $6.00 per share and has a maximum value of up to $5.2 billion. The FTC ended the waiting period early; closing is expected by year-end, subject to further regulatory approvals. The CVR payout is contingent on approval of Efruxifermin for treatment of MASH by June 2031; earlier Phase‑2b data and a buy recommendation from H.C. Wainwright underpin the clinical potential. » More on de.investing.com

At the AASLD annual meeting, Akero presented new analyses showing that Efruxifermin reduced fibrosis and the risk of disease progression in patients with metabolically associated steatohepatitis (MASH). Non‑invasive markers and AI‑supported digital pathology confirmed significant improvements in fibrosis and septal area, particularly in compensated cirrhosis. Efruxifermin is currently being further evaluated in three phase 3 studies (SYNCHRONY Histology, SYNCHRONY Outcomes, SYNCHRONY Real‑World), and the data are being presented in several talks and posters. » More on de.investing.com